234 related articles for article (PubMed ID: 9814369)
1. Trastuzumab and capecitabine for metastatic breast cancer.
Med Lett Drugs Ther; 1998 Nov; 40(1039):106-8. PubMed ID: 9814369
[No Abstract] [Full Text] [Related]
2. Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer.
Benjamin L; Buthion V; Iskedjian M; Farah B; Rioufol C; Vidal-Trécan G
J Med Econ; 2013; 16(1):96-107. PubMed ID: 22970840
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib in metastatic breast cancer.
Frenel JS; Bourbouloux E; Berton-Rigaud D; Sadot-Lebouvier S; Zanetti A; Campone M
Womens Health (Lond); 2009 Nov; 5(6):603-12. PubMed ID: 19863462
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
Yamamoto D; Iwase S; Kitamura K; Odagiri H; Yamamoto C; Nagumo Y
Cancer Chemother Pharmacol; 2008 Mar; 61(3):509-14. PubMed ID: 17516068
[TBL] [Abstract][Full Text] [Related]
5. Moving forward with capecitabine: a glimpse of the future.
Biganzoli L; Martin M; Twelves C
Oncologist; 2002; 7 Suppl 6():29-35. PubMed ID: 12454317
[TBL] [Abstract][Full Text] [Related]
6. Dose scheduling--Herceptin.
Leyland-Jones B
Oncology; 2001; 61 Suppl 2():31-6. PubMed ID: 11694785
[TBL] [Abstract][Full Text] [Related]
7. [Breast Cancer Conference. Trastuzumab and capecitabine in the treatment of advanced breast cancer. Milano, 6-7 June 2002].
Longo F; Mansueto G
Tumori; 2002; 88(5):A1-10. PubMed ID: 12489530
[No Abstract] [Full Text] [Related]
8. State-of-the-art chemotherapy for advanced breast cancer.
Piccart MJ; Awada A
Semin Oncol; 2000 Oct; 27(5 Suppl 9):3-12. PubMed ID: 11049051
[TBL] [Abstract][Full Text] [Related]
9. [High cost of trastuzumab for the treatment of mammary carcinoma in The Netherlands].
Offerhaus L
Ned Tijdschr Geneeskd; 2006 Jun; 150(25):1426-7; author reply 1427. PubMed ID: 16841595
[No Abstract] [Full Text] [Related]
10. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
Schaller G; Fuchs I; Gonsch T; Weber J; Kleine-Tebbe A; Klare P; Hindenburg HJ; Lakner V; Hinke A; Bangemann N
J Clin Oncol; 2007 Aug; 25(22):3246-50. PubMed ID: 17577021
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine and docetaxel combination for the treatment of breast cancer.
Morishita M; Leonard RC
Womens Health (Lond); 2008 Jan; 4():11-22. PubMed ID: 19072447
[TBL] [Abstract][Full Text] [Related]
12. Drug update: emerging therapies for breast cancer.
Valgus JM
Cancer Pract; 1999; 7(2):100-3. PubMed ID: 10352069
[No Abstract] [Full Text] [Related]
13. Complete response of severe symptomatic bone marrow metastases from heavily pretreated breast cancer with a 3-weekly trastuzumab schedule. A clinical case.
Rossi A; Colantuoni G; Cantore N; Panico L; De Chiara G; Ferbo U; Gridelli C
Anticancer Res; 2004; 24(1):317-9. PubMed ID: 15015614
[TBL] [Abstract][Full Text] [Related]
14. New treatment strategies provide more options for patients with breast cancer.
Hampton T
JAMA; 2008 Jul; 300(4):381-2. PubMed ID: 18647973
[No Abstract] [Full Text] [Related]
15. Trastuzumab in breast cancer.
Mastrianni DM
N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470953
[No Abstract] [Full Text] [Related]
16. Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials.
Tripathy D
Oncologist; 2007 Apr; 12(4):375-89. PubMed ID: 17470680
[TBL] [Abstract][Full Text] [Related]
17. [Capecitabine: an oral chemotherapeutic agent against metastatic breast and colorectal cancer].
Calzas Rodríguez J; de la Nogal Fernández B; Arrieta Garmendia JM; Lastra Aras E; García Castaño A; Barrio Gil-Fournier A; García Girón C
Farm Hosp; 2003; 27(3):171-8. PubMed ID: 12835819
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
Goldenberg MM
Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab faces trials, clinical and otherwise.
Tuma RS
J Natl Cancer Inst; 2006 Mar; 98(5):296-8. PubMed ID: 16507822
[No Abstract] [Full Text] [Related]
20. Trastuzumab and metastatic breast cancer: trastuzumab use in Australia--monitoring the effect of an expensive medicine access program.
Pearson SA; Ringland CL; Ward RL
J Clin Oncol; 2007 Aug; 25(24):3688-93. PubMed ID: 17704417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
